This pilot study will try to demonstrate metabolic changes in spine lesions treated by Augmentation and Ablation, according to existing standards of practice. Our purpose is to show the efficacy of a new radiofrequency ablation (RFA) in combination with augmentation, using a percutaneous ablation device (Osteocool-Medtronic) in the treatment of secondary vertebral bone tumor, avoiding concurrent bias related to other treatments of the disease.
Only patient supposed to undergo percutaneous vertebral augmentation for secondary osteolytic and mixed (lytic and sclerotic) spine tumors with one to three active lesions will be enrolled. Lesions to be treated must be metabolically active on Positronic Emission Computed Tomography (PET-CT), performed during the last month. Patients will be informed and sign and inform consent. Patients will be treated with Augmentation and Ablation (Osteocool-Medtronic). Post treatment patients will be submitted to a new PET-CT in order to verify activity on treated site.
Study Type
OBSERVATIONAL
Enrollment
16
Percutaneous Tumor Ablation of Spine Lesions followed by Polymer Augmentation
3rd Department of Radiology, NKUOA, General Hospital "LAIKON"
Athens, Athens, Greece
RECRUITINGPET-CT
Positron Emission Tomography (PET) Activity
Time frame: SUV measurement of PET in 24 hours
Greek Brief Pain Index (GBPI)
NUMERIC VISUAL SCORE (NVS) OF PAIN AND MOBLITY
Time frame: 1 MONTH, 6 MONTHS, 12 MONTHS
MARIA IOANNIDI, MD
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.